Amorfix reaches milestone in blood test for Alzheimer's disease

By Jennifer Chiou

New York, Sept. 5 - Amorfix Life Sciences Inc. and the Ontario Genomics Institute announced the achievement of a technical milestone after demonstrating that Amorfix's Epitope Protection technology is able to detect protected sites within Abeta amyloid aggregates, which are formed in Alzheimer's disease.

With this advancement, Amorfix said it will commit additional resources to develop an ultra-sensitive blood test for Alzheimer's disease, EP-AD, based its patent-pending EP technology and based on the January 2006 subscription agreement, the institute will invest its $50,000 second tranche into the company.

Alzheimer's disease is associated with an accumulation of protein aggregates, called amyloid, in the brain, the company said, noting that it believes Abeta amyloid aggregates are also present in the circulation in Alzheimer's patients.

Toronto-based Amorfix is a theranostics company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.